T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

The T2Biothreat Panel detects six biothreat pathogens and runs on the FDA-cleared T2Dx Instrument The T2Biothreat Panel detects six biothreat pathogens and runs on the FDA-cleared T2Dx Instrument

T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel

LEXINGTON, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today it has rescheduled its first quarter 2023 financial results reporting to before market open on Tuesday, May 23, 2023. Company management will host a corresponding conference call beginning at 8:30 a.m. Eastern Time.

T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023

SCYNEXIS

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C.

WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens

LEXINGTON, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has rescheduled its first quarter 2023 financial results reporting to before market open on Monday, May 22, 2023. Company management will host a corresponding conference call beginning at 8:30 a.m. Eastern Time.

T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023

LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today it has postponed its first quarter 2023 earnings release and conference call. The delay is a result of additional time required to finalize the filing of the Company's SEC Form 10-Q.

T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results

LEXINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2023 after market close on Monday, May 15, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report First Quarter 2023 Financial Results on May 15, 2023

LEXINGTON, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted new clinical data supporting the T2Bacteria® Panel and the T2Candida® Panel, that was recently presented at the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Copenhagen, Denmark. The data demonstrates the speed, accuracy and clinical benefits of the T2Dx® Instrument and T2 Biosystems' sepsis panels.

T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference

AngioDynamics

Apollomics Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the availability of a new webinar and white paper highlighting the T2Candida® Panel clinical data and best practices from real world use within Medical Intensive Care Units (MICU).

T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices

CleanSpark

CXApp Inc

Generation Bio

Ferroglobe

PLBY Group

Proterra

SoundHound AI Inc

Virios Therapeutics

Virgin Orbit Holdings

Penny stocks to watch this week under $5 The post Best Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 10 To Watch Under $5

Penny stocks to watch under $5 this week. The post Penny Stocks To Buy Under $5?

Penny Stocks To Buy Under $5? 7 To Watch This Week

LEXINGTON, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today affirmed plans to add detection of the fungal pathogen Candida auris to the Company's FDA-cleared and CE marked T2Candida® Panel.

T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel

Penny Stocks Under $5 To Watch Right Now. The post Penny Stocks To Buy Under $5?

Penny Stocks To Buy Under $5? 3 To Watch This Week

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants John Sperzel - Chairman and CEO John Sprague - CFO Conference Call Participants Mark Massaro - BTIG Ben Haynor - Alliance Global Partners Kyle Mikson - Canaccord Genuity Operator Good day everyone and welcome to the T2 Biosystems Inc. Fourth Quarter and Full-Year 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

T2 Biosystems, Inc. (TTOO) Q4 2022 Earnings Call Transcript

Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument placements in 2022 Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument placements in 2022

T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results

LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2022 after market close on Monday, March 13, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

T2 Biosystems (NASDAQ: TTOO ) stock continues to drop on Wednesday as investors react to news of a public stock offering. The big news today is the company announcing additional details of its public stock offering.

Why Is T2 Biosystems (TTOO) Stock Down 23% Today?

LEXINGTON, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) today announced the pricing of its previously announced underwritten public offering of 11,111,111 shares of common stock (or common stock equivalents) and warrants to purchase up to 22,222,222 shares of common stock at a combined public offering price of $1.08 per share of common stock (or common stock equivalent) and accompanying warrants, for initial gross proceeds of approximately $12 million, before underwriting discounts and commissions and offering expenses. The warrants have an exercise price of $1.08 per share, are exercisable immediately and will expire five years following the date of issuance.

T2 Biosystems Announces Pricing of $12 Million Public Offering

T2 Biosystems (NASDAQ: TTOO ) stock is falling hard on Tuesday as investors react to a proposed public offering from the company. T2 Biosystems doesn't reveal much in the way of details about its proposed public offering.

Why Is T2 Biosystems (TTOO) Stock Down 21% Today?

LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents) and warrants to purchase shares of its common stock. All of the securities are being offered by T2 Biosystems. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

T2 Biosystems Announces Proposed Public Offering

Results demonstrated very high sensitivity and specificity across all six biothreat targets exceeding target performance requirements Results demonstrated very high sensitivity and specificity across all six biothreat targets exceeding target performance requirements

T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

Ally Financial

Amyris

Black Hills

Invitae

Shake Shack

World Acceptance

In order for a free market to operate, investors must be willing to participate in both sides of the transaction, which brings us to the topic of the stocks to short this week. If you're feeling optimistic about the pessimistic trajectory of embattled enterprises, this list may be for you.

The 7 Best Stocks to Short This Week

LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation's (“Cohen Foundation”) LymeX Diagnostics Prize. The goal of the multiphase LymeX Innovation Accelerator (LymeX) prize competition is to nurture the development of diagnostics toward Food and Drug Administration (FDA) review.

T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022 Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results

LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.

News for T2 Biosystems Stock (TTOO)